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Abstract
Background: The long-term dose-effect relationship for specific cardiac structures in mediastinal
radiotherapy has rarely been investigated. As part of an interdisciplinary project, the 3-D dose
distribution within the heart was reconstructed in all long-term Hodgkin's disease survivors (n =
55) treated with mediastinal radiotherapy between 1978 and 1985. For dose reconstruction,
original techniques were transferred to the CT data sets of appropriate test patients, in whom left
(LV) and right ventricle (RV), left (LA) and right atrium (RA) as well as right (RCA), left anterior
descending (LAD) and left circumflex (LCX) coronary arteries were contoured. Dose-volume
histograms (DVHs) were generated for these heart structures and results compared between
techniques.
Results: Predominant technique was an anterior mantle field (cobalt-60). 26 patients (47%) were
treated with anterior mantle field alone (MF), 18 (33%) with anterior mantle field and monoaxial,
bisegmental rotation boost (MF+ROT), 7 (13%) with anterior mantle field and dorsal boost
(MF+DORS) and 4 (7%) with other techniques. Mean ± SD total mediastinal doses for MF+ROT
(41.7 ± 3.5 Gy) and for MF+DORS (42.7 ± 7.4) were significantly higher than for MF (36.7 ± 5.2
Gy). DVH analysis documented relative overdosage to right heart structures with MF (median
maximal dose to RV 129%, to RCA 127%) which was siginificantly reduced to 117% and 112%,
respectively, in MF+ROT. Absolute doses in right heart structures, however, did not differ between
techniques. Absolute LA doses were significantly higher in MF+ROT patients than in MF patients
where large parts of LA were blocked. Median maximal doses for all techniques ranged between
48 and 52 Gy (RV), 44 and 46 Gy (LV), 47 and 49 Gy (RA), 38 and 45 Gy (LA), 46 and 50 Gy (RCA),
39 and 44 Gy (LAD) and 34 and 42 Gy (LCX).
Conclusion: In patients irradiated with anterior mantle-field techniques, high doses to anterior
heart portions were partly compensated by boost treatment from non-anterior angles. As the
threshold doses for coronary artery disease, cardiomyopathy, pericarditis and valvular changes are
assumed to be 30 to 40 Gy, cardiac toxicity must be anticipated in these patients. Thus, dose
distributions in individual subjects should be correlated to the corresponding cardiovascular
findings in these long-term survivors, e. g. by cardiovascular magnetic resonance imaging.
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The risk of cardiac toxicity associated with mediastinal
radiotherapy is well known. Multiple studies have
addressed the prevalence of valvular disease, myocardial
changes, coronary artery disease and the resulting risk of
myocardial infarction or death from cardiac disease after
thoracic radiotherapy, in particular after mantle-field irra-
diation in Hodgkin's disease [1-4]. Whereas the introduc-
tion of large radiation portals for concomitant irradiation
of adjacent nodal sites by Kaplan [5] and implementation
of effective multi-agent chemotherapy regimens by De
Vita [6] led to a significant increase in cure rates in the
1970s and 1980s, clinical trials in the 1990s focussed on
the reduction of radiotherapy doses and irradiated vol-
umes. For instance, a multi-center trial of the German
Hodgkin's Lymphoma Study Group (GHSG) established
that in intermediate-risk patients cure rates are identical
after extended-field and involved-field radiotherapy with
30 Gy, each following chemotherapy with COPP/ABVD
[7]. In a subsequent series of trials, involved-field doses of
20 Gy and 30 Gy were compared in low-risk and interme-
diate-risk groups and early analyses in intermediate-risk
patients suggest equivalence [8].
Despite these efforts to reduce radiation-induced late tox-
icity, of which heart disease is one aspect, oncologists and
cardiologist are still seeing survivors of Hodgkin's disease
treated in earlier decades, e. g. with extended-field radio-
therapy of approximately 40 Gy, with or without chemo-
therapy.
Although some information is available on threshold
radiation doses for certain cardiac toxicities such as coro-
nary artery disease, pericarditis, or valvular changes, esti-
mating that a critical dose range is between 30 and 40 Gy
[9], a correlation of damage to particular cardiac struc-
tures and dose to the corresponding region has rarely been
attempted, due to a lack of 3-D computed tomography
data sets for patients reported in published series. Some
authors have calculated the heart dose at a certain depth
and used this value for statistical analysis [3].
In the present analysis, we reconstructed the dose to car-
diac structures in patients treated with anterior mantle-
field techniques, with or without boost, for Hodgkin's dis-
ease between 1978 and 1985. Dose-volume histograms
were generated for heart cavities and coronary arteries by
applying the information on original radiotherapy tech-
nique to CT data sets of test patients. The information
thus obtained will form the basis of a detailed analysis of
patterns of cardiac damage within an interdisciplinary
project of cardiologists and radiation oncologists.
Results
Of the 55 patients, 26 (47%) were treated with anterior
mantle field (MF) alone, 18 (33%) with anterior mantle
field and monoaxial, bisegmental rotation boost
(MF+ROT), 7 (13%) with anterior mantle field and dorsal
boost (MF+DORS) and 4 (7%) with other techniques, e.
g. three-field technique (OTHER). Typical reconstructed
dose distributions of anterior mantle field, rotation boost
Reconstruction of dose distribution for typical cases of ante-rior mantle field (A), monoaxial, bisegmental rot tion boost (B) a d dorsal b ost (C)Figure 1
Reconstruction of dose distribution for typical cases of ante-
rior mantle field (A), monoaxial, bisegmental rotation boost 
(B) and dorsal boost (C). Note the contours of heart cavities 
and position of coronary arteries (RA: right atrium, LA: left 
atrium, RV: right ventricle, LV: left ventricle, yellow arrow: 
right coronary artery, red arrow: left anterior descending 
(LAD) artery, green arrow: left circumflex (LCX) artery).
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fields were typically treated at 120 cm source-skin dis-
tance, single surface dose 1.3 Gy, single dose at prescrip-
tion point (at approximately 7 cm depth) 2.0 Gy. For
dorsal and rotation boost, the source-isocenter distance
was 60 cm and typical single doses were 2 Gy at isocenter.
Mean ± SD total prescribed doses in the mid-third of the
mediastinum were 36.7 ± 5.2 Gy for MF, 41.7 ± 3.5 Gy for
MF+ROT (p = 0.003), 42.7 ± 7.4 for MF+DORS (p = 0.01)
and 41 ± 2 Gy for OTHER. The mean contribution of
boost doses to these total doses were 9.8 ± 2.2 Gy in
MF+ROT and 10 ± 2.3 Gy in MF+DORS.
The results of a dose-volume histogram analysis of cardiac
structures are shown in Table 1. The median values of
individual minimal, maximal, mean and median doses
were calculated for both atria and ventricles as well as for
coronary arteries. Doses are given as relative values, to
underscore overdosage to particular cardiac structures
with specific techniques, and as absolute values in Gy, tak-
ing into account the prescribed total doses which differed
between techniques. The absolute values represent an esti-
mation of the dose the patients actually received in partic-
ular regions of the heart.
With anterior mantle field alone, overdosage to anterior
portions of the heart was obvious (Table 1, Fig. 1). For
instance, median maximal doses were 129% (up to 147%
Table 1: Results of dose-volume histogram analysis. Results of dose-volume histogram (DVH) analysis of cardiac structures (RV: right 
ventricle, RA: right atrium, LV: left ventricle, LA: left atrium, RCA: right coronary artery, LAD: left anterior descending artery, LCX: 
left circumflex artery). Median (min-max) doses are given for patients treated with mantle field alone (MF), mantle field + rotation 
boost (MF+ROT) and mantle field + dorsal boost (MF+DORS), both as relative doses (in %) and absolute doses (in Gy). Values 
significantly different from MF are indicated by bold print (*= p < 0.05). Significantly higher relative doses to RV, RA and RCA with MF 
alone are compensated by reduced total prescription doses for MF technique and by sparing of right heart structures with boost 
techniques, resulting in comparable absolute total doses between techniques. (# indicates DVH parameters in which a significant 
inverse correlation between 2-D heart area shielded by block and the respective DVH value was observed.)
structure relative dose [%] absolute dose [Gy]
(# = significant 
correlation 2D–
3D)
MF n = 26 MF+ROT n = 18 MF+DORS n = 7 MF n = 26 MF+ROT n = 18 MF+DORS n = 7
RV min # 30 (16–98) 24 (12–49) 18 (14–87) 11 (3–35) 11 (5–22) 8 (6–40)
RV max 129 (108–147) 117 (98–141)* 114 (94–124)* 49 (23–58) 48 (43–58) 52 (39–52)
RV median 117(49–132) 101(64–118)* 94 (88–114) 43 (18–53) 43 (22–52) 43 (36–48)
RV mean # 114 (61–127) 99 (74–112) 85 (80–104) 41 (19–52) 41 (25–47) 37 (35–46)
LV min 18 (12–46) 16 (9–27) 15 (10–20) 7 (2–16) 8 (4–11) 6 (5–9)
LV max 119 (32–147) 107 (52–129) 96 (92–122) 46 (12–53) 45 (18–55) 44 (39–51)
LV median # 42 (17–99) 41 (19–95) 40 (22–55) 16 (6–41) 18 (7–39) 17 (10–25)
LV mean # 56 (17–91) 50 (26–83) 47 (33–58) 22 (6–35) 23 (10–34) 19 (15–25)
LA min 84 (28–97) 79 (48–95) 73 (40–89) 30 (10–37) 34 (16–40) 32 (18–37)
LA max 102 (84–116) 106 (86–124) 93 (85–110) 38 (18–46) 45 (36–49)* 43 (35–46)
LA median 92 (76–106) 98 (79–108) 80 (75–103) 35 (16–41) 41 (33–45)* 36 (33–43)
LA mean 92 (76–106) 97 (78–107) 81 (75–103) 35 (16–41) 41 (33–45)* 36 (33–43)
RA min 86 (20–103) 75 (37–104) 75 (43–101) 31 (8–38) 30 (17–44) 33 (19–42)
RA max 123 (100–142) 116 (99–143) 107 (91–119)* 47 (21–55) 49 (42–57) 49 (38–50)
RA median 105 (76–122) 101 (88–125) 90 (86–110) 39 (19–48) 43 (33–51) 41 (35–46)
RA mean 105 (68–122) 100 (84–122) 89 (86–110) 39 (19–47) 42 (32–50) 41 (35–46)
RCA min 101 (48–128) 90 (58–108) 84 (67–99) 37 (19–51) 38 (23–47) 38 (31–42)
RCA max 127 (99–147) 112 (93–144)* 109 (94–122)* 48 (22–56) 46 (40–56) 50 (39–51)
RCA median 120 (90–141) 104 (89–125)* 103 (92–120) 45 (22–55) 43 (37–55) 47 (38–50)
RCA mean 116 (91–136) 102 (86–121)* 96 (90–11,6) 44 (21–54) 42 (36–53) 44 (37–48)
LAD min # 23 (15–80) 20 (11–34) 18 (13–33) 9 (3–28) 10 (5–14) 8 (6–15)
LAD max # 109 (25–139) 104 (48–122) 92 (68–120) 39 (9–55) 44 (16–50) 40 (31–50)
LAD median # 60 (19–121) 66 (28–113) 39 (26–108) 20 (7–48) 30 (10–47) 18 (12–45)
LAD mean # 61 (19–112) 60 (30–96) 53 (35–81) 23 (7–46) 28 (10–39) 22 (16–34)
LCX min # 68 (22–93) 66 (38–91) 53 (28–79) 25 (8–37) 29 (13–38) 22 (13–33)
LCX max 91 (44–111) 96 (56–112) 87 (81–108) 34 (16–43) 42 (19–46)* 40 (33–45)
LCX median # 80 (22–95) 79 (42–95) 75 (40–95) 29 (8–39) 35 (14–40) 31 (18–40)
LCX mean # 79 (26–96) 81 (43–94) 71 (46–92) 29 (9–39) 35 (15–40)* 29 (21–39)Page 3 of 8
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142%) in the right atrium and 127% (up to 147%) in the
right coronary artery. Compared with anterior mantle
field alone, median maximal doses were significantly
reduced to 117% in the right ventricle and 112% in the
right coronary artery by combining the anterior mantle
field technique with a monoaxial, bisegmental rotation
boost technique (Table 1). Patients in whom the anterior
mantle field was combined with a dorsal boost had signif-
icantly reduced median maximal doses the right atrium,
107%, and the right coronary artery, 109%.
When absolute doses in Gy were compared, the signifi-
cant differences in dose to the right heart structures were
lost, as patients treated with anterior mantle field alone
received lower total mediastinal doses (mean 36.7 Gy)
than patients in the MF+ROT (41.7 Gy) and MF+DORS
(42.7 Gy) groups, indicating that the use of these boost
techniques permitted dose increases in the mediastinum
while maintaining the dose levels in the right heart struc-
tures seen with reduced-dose anterior mantle field alone.
However, the use of a rotation boost technique led to sig-
nificantly increased median absolute doses to the left
atrium and the left circumflex artery, compared to mantle
field alone. With the different techniques, median maxi-
mum doses to the right and left ventricle were between 48
and 52 Gy and between 44 and 46 Gy, respectively. In the
coronary arteries, median maximal doses ranged between
46 and 50 Gy for the right coronary artery, 39 and 44 Gy
in the left anterior descending artery and 34 and 42 Gy in
the left circumflex artery.
To investigate the effect of shielding part of the heart with
lead blocks in anterior mantle fields on the DVH results of
cardiac structures (all patients and techniques considered
together), we first quantified the percentage of 2-D heart
area on the portal film shielded by lead blocks. The mean
(± SD) percentage of the heart contour shielded by blocks
was 36.3 ± 8.9% (range 18.2–53%). This percentage cor-
related inversely with several DVH parameters, e. g. the
mean doses to both ventricles (Table 1), indicating spar-
ing of the respective structures. All significant correlations
applied equally to relative doses (in %) and absolute total
doses (in Gy).
Discussion
Irradiation of the mediastinum with anterior mantle field
techniques, alone or followed by boost techniques, repre-
sents an outdated treatment technique that was, however,
state of the art in the 1970s. The mantle field, defined as
"a single anteroposterior radiation therapy field designed
to treat in continuity the major lymph node-bearing areas
above the diaphragm while maximally shielding the lungs
in patients with lymphoma" [10] was first introduced by
Kaplan in 1956 [5] and replaced the irradiation of individ-
ual nodal sites with separate fields. Extended-field radio-
therapy of Hodgkin's lymphoma with megavoltage
equipment, using e. g. the mantle field, was introduced in
centers in Germany in the early to mid-1970s [11,12].
Concerns about the dose to the spinal cord and technical
reasons led several centers to use anterior mantle fields
alone or anteriorly weighted opposing fields rather than
equally weighted opposing fields for mantle treatment
[13]. The limited source-to-isocenter distance of cobalt
machines and the necessity of large irradiation fields
required extended source-to-skin distances which were
achieved by positioning the patient on the floor in the
supine position and placing blocks on a block holder
above the patient. Introducing a dorsal mantle field
would have required changing the patient position to
prone and introduced unwanted dosimetric uncertainties.
In cases where underdosage to the posterior mediastinum
with an anterior mantle field was a concern, lateral
oblique, dorsal or rotation boost techniques were
employed [13]. Boost treatments could be performed on
the treatment table, as fields were shorter due to limited
treated mediastinal volumes. Although most reports
focussed on cardiac toxicity after treatment with opposing
photon beams, anterior mantle field technique in particu-
lar has been associated with high rates of late toxicity such
as constrictive pericarditis [14-16].
Apart from a historic interest, a 3-D reconstruction of dose
distributions achieved with such techniques is relevant
because patients thus treated may require special cardio-
logical attention. In the present study, 39% of the initial
study cohort are alive today. Thus, detailed knowledge of
the individual cardiac dose distribution in long-term sur-
vivors of mediastinal radiotherapy may help to identify
patients at risk and aid the cardiologist in the interpreta-
tion of the patients' complaints and findings. Besides, the
correlation of the reconstructed formerly applied 3-D
dose distribution with the corresponding cardiovascular
findings as obtained with non-invasive cardiac imaging
techniques (e. g. cardiovascular magnetic resonance imag-
ing [17]), may expand our knowledge of dose-effect rela-
tionships of cardiac structures such as the myocardium,
coronary arteries or heart valves. It should be noted that
solely studying the long-term survivors could potentially
introduce a bias regarding the cardiac dose distribution in
the overall cohort of n = 143 patients treated in the study
period. The causes of death of the n = 88 non-survivors are
not known and it can not be excluded that the cardiac
doses differed between survivors and non-survivors. How-
ever, in preparation of a clinical investigation of long-term
survivors, the dose reconstruction now presented was lim-
ited to this subgroup.
Although the cardiac effects of thoracic radiotherapy have
been extensively studied in the 1980s and 1990s [3,4],Page 4 of 8
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structures of the heart and consecutive patterns of cardio-
vascular structural and functional abnormalities are scarce
in the literature. In a report on 144 survivors of mediasti-
nal radiotherapy for Hodgkin's lymphoma, Glanzmann et
al. calculated the total doses to the "anterior heart region"
to be between 30 and 42 Gy in 93% of patients [3]. While
the relative risk for myocardial infarction and for infarc-
tion or sudden death was 4.2 and 6.7, respectively, and
valvular thickening was observed in 60% of patients after
30 years of follow-up, patients without additional cardiac
risk factors (smoking, hypertension, hypercholesterine-
mia) were found to have no increased risk of cardiac
events. In a recent systematic evaluation of Hodgkin's dis-
ease survivors 14 years (median) after chest radiotherapy,
42% had significant valvular defects, 75% conduction
defects, and 30% a reduced peak oxygen uptake, a predic-
tor of mortality in heart failure [1]. Further, a review of
radiation-associated cardiovascular disease by Adams et
al. suggests the following dose levels ("total cumulative
radiation exposure to the chest") as a guideline for the
selection of patients to be screened for cardiovascular dis-
ease [9]: pericarditis above 35 Gy, cardiomyopathy above
35 Gy (or above 25 Gy if anthracyclines were used), coro-
nary artery disease above 30 Gy, valvular disease above 40
Gy. These data indicate that it may be of importance to
reconstruct the local dose distribution and especially the
localization of dose peaks if the total prescription dose
was in the range of 30 to 40 Gy, in such patients in order
to estimate the patients' individual cardiovascular risk,
facilitating timely cardiovascular diagnostic procedures
and adequate treatment before the occurrence of compli-
cations.
Cardiac structures now chosen for contouring and DVH
analysis were limited by their visibility on standard non-
enhanced planning CT scans. The heart cavities were con-
toured due to practicality although one could argue that
the target tissue is the myocardium and not the heart con-
tent. Such considerations are unresolved until today in
other body regions, e. g. concerning contouring of the
whole rectum vs. the rectal surface in pelvic radiotherapy.
Despite poor visibility, we contoured the major coronary
arteries as we expected these to be major target organs
mediating radiation-induced cardiac toxiticity, hypothe-
sizing that with the anterior mantle technique, coronary
arteries would differ in total dose resulting in specific pat-
terns of coronary artery disease, as suggested in the older
literature [18].
In the 55 long-term survivors now analyzed, anterior
mantle-field technique alone was associated with a
median maximal dose to the right ventricle of 128% and
to the right coronary artery of 127%, with even higher
doses in individual patients. Obviously, delivering part of
the radiation dose via other techniques with lateral or dor-
sal beam entry reduced this relative overdosage in anterior
portions of the heart. In patients treated with anterior
mantle field followed by rotation or dorsal boost, signifi-
cantly higher total doses could be delivered than with
mantle field alone, without further increases in dose to
anterior heart structures. This was achieved at the expense
of irradiating parts of the left atrium which were either
blocked or outside the high-dose region in the mantle-
field technique. It is currently unclear if patterns of radia-
tion-associated coronary artery disease differ from those
seen in unirradiated patients. An older angiographic study
in 15 patients with coronary artery disease after thoracic
radiotherapy for different tumor entities (nine Hodgkin's
lymphomas) found predominant left main and right
ostial coronary artery disease [18]. Although the left main
artery was not analyzed in the present study due to its
short presentation on CT, high doses to the anterior heart,
as resulting from anterior mantle field technique, could
explain these locations.
Despite these technical efforts, the median maximal total
doses to the right heart and right coronary artery were 48
Gy and 46 Gy, respectively. These structures also received
the highest maximal doses in individual patients (58 Gy
and 56 Gy, respectively). With a more modern opposed-
field technique using a linear accelerator, in comparison,
the overdosage to anterior heart structures should not be
more than 6% of a manually calculated dose [19]. The
adoption of involved-field radiotherapy with doses not
higher than 30 Gy in favorable and intermediate Hodg-
kin's disease [7], e.g. in the current and previous genera-
tions of trials in Germany, has therefore reduced the
maximum dose to any cardiac structure to slightly over 30
Gy. While the combination with chemotherapy may pro-
vide additional cardiotoxic effects, patients without medi-
astinal involvement, who previously would have been
treated with an extended field in the form of a mantle
field, would receive no dose to the heart in involved-field
radiotherapy.
The 2-D percentage of shielded heart area correlated
inversely with several DVH parameters. Especially the left
and right ventricle as well as the branches of the left coro-
nary artery benefitted from blocking. In structures that
were partially blocked in most patients, such as left and
right ventricle, mean and median dose but not minimum
or maximum dose were correlated with the blocked heart
area. The dose to the left and right atrium as well as the
right coronary artery was not associated with heart shield-
ing, suggesting that these structures are exposed to high
radiation doses even with extensive heart shielding. This
knowledge may be of interest even in the days of lower-
dose involved-field radiotherapy when the position of
coronary arteries is not usually considered.Page 5 of 8
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D imaging studies in these patients. Variations in cardiac
anatomy, e. g. branching of coronary arteries, could not be
considered in the present design. The current data do not
provide precise quantitative data on dose distribution in
individual patients. However, for the whole cohort, the
calculated doses should be a very good approximation. As
part of an ongoing interdisciplinary study between cardi-
ologists, radiologists and radiation oncologists, Hodg-
kin's disease survivors will be invited for extensive
cardiologic tests including cardiac MRI [17]. As previously
suggested [20], this project opens up the possibility to
reconstruct the radiation dose in the individual patient's
3-D data set and directly correlate this with individual car-
diac pathology. Even this approach, although considering
individual anatomy, will not be able to take into account
changes in cardiac morphology between the time of treat-
ment (about 25 years ago) and clinical reevaluation.
Conclusion
Our investigation documented the 3-D dose distribution
of patients treated with anterior mantle-field technique 25
years ago. This technique, in some patients followed by
mediastinal boost irradiation from non-anterior direc-
tions, was associated with dose peaks in anterior portions
of the heart, especially the right ventricle and right coro-
nary artery. Given the relatively high total radiation doses
prescribed in this treatment era, our data set should pro-
vide a solid base for a detailed analysis of cardiac dose-
effects in long-term Hodgkin's disease survivors.
Methods
Patients
Between 1978 and 1985, 143 patients were treated with
mediastinal radiotherapy for Hodgkin's disease at the
University of Würzburg. Of these, n = 55 (38.5%) were
alive at the time of analysis in March of 2003 and were
included in the present analysis, as these patients are
potentially available for future cardiologic evaluation.
Mean ± SD age at the time of treatment was 25 ± 10 years
(range 6 to 49 years). A review of patient charts yielded the
patient characteristics shown in Table 2.
Dose reconstruction
For 2-D evaluation of the portal films of mantle field irra-
diation, heart borders were contoured and films scanned.
Images were quanititatively analyzed using image process-
ing software Scion Image vs. 4.0.2 (Scion Co., Frederick/
MA, USA). The 2-D heart area was measured as well as the
portion of the heart shielded by lead blocks.
For 3-D dose reconstruction, each treated patient was first
assigned to one of four test patients (treated more recently
for Hodgkin's disease) most closely resembling the anat-
omy of the treated patient, in particular with regard to
heart shape. In each of the test patients, for whom plan-
ning CT studies in 1-cm slice thickness and spacing were
available, the following structures were contoured in
Helax TMS (Nucletron, Veenendal, Netherlands) treat-
ment planning system on the basis of a digital atlas of tho-
racic CT anatomy [21] and of recent publications on cross-
sectional heart anatomy [22,23]: left atrium, left ventricle,
right atrium, right ventricle, left anterior descending
(LAD) artery, left circumflex (LCX) artery, right coronary
artery (RCA).
For reconstruction of the cardiac dose distribution, the
original mantle-field portal film of the treated patient was
matched to a digital radiographic reconstruction from a 0
degree angle of the test patient (Fig. 2). This matching pro-
cedure was based on specific corresponding landmarks on
the heart outline of the treated patient and test patient,
resulting in good matching results with regard to the
heart, sometimes at the expense of incorrect matching
concerning the lungs or bony structures, which were not
part of the current analysis. All treatment details (source-
skin distance, depth of prescription point, surface dose,
Table 2: Patient Characteristics of n = 55 living patients treated 
with mediastinal radiotherapy for Hodgkin's disease between 
1978 and 1985.
characteristics n (%)
sex male 29 (53%)
female 26 (47%)
stage I 13 (24%)
II 28 (51%)
III 14 (25%)
B symptoms 16 (29%)
risk factors a 0 (0%)
b 1 (2%)
c 13 (24%)
d 10 (18%)
histology lymphocyte-predominant 7 (13%)
nodular sclerosing 36 (65%)
mixed 10 (18%)
not available 2 (4%)
involved regions cervical 27 (49%)
supra-/infraclavicular 31 (56.4%)
axilla 13 (23,7%)
mediastinum 30 (54.5%)
paraaortic 2 (4%)
inguinal 3 (5%)
spleen 11 (20%)
treatment radiotherapy alone 33 (60%)
chemoradiation 22 (40%)Page 6 of 8
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Radiation Oncology 2006, 1:10 http://www.ro-journal.com/content/1/1/10dose at prescription dose, field size) were then entered
into the planning system. All original treatments were per-
formed with a cobalt-60 unit. Mantle-field irradiation was
performed with patients positioned on the floor in supine
position at typical source-skin distances of 120 cm. To
reconstruct techniques other than mantle-field (rotation
or dorsal boost techniques), treatment plans were recon-
structed in a similar fashion, using simulation films docu-
menting the anatomic isocenter position.
Statistics
For each patient, all plans contributing to the mediastinal
dose were added according to the total dose in Gy to
which they were used. Different fractionation schemes
were not corrected for. Cumulative dose-volume histo-
grams for cardiac substructures were generated both for
absolute doses (in Gy) and for relative doses (in %). DVH
data were compared between groups treated with different
techniques (mantle-field alone vs. mantle-field followed
by different boost techniques) using the Kruskal-Wallis
test with Dunn's post-hoc test (p < 0.05 considered signif-
icant). The correlation between 2-D area of heart blocked
and 3-D DVH parameters was tested using the Spearman
rank test.
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